Tata Consultancy Services (TCS)

Similar documents
Tata Consultancy Services (TCS)

Tata Consultancy Services (TCS)

Tech Mahindra ACCUMLATE. Performance Highlights `495 `526. CMP Target Price. 2QFY2018 Result Update IT

Wipro ACCUMULATE. Performance Highlights CMP. `539 Target Price `582. 1QFY2017 Result Update IT. Investment Period 12 Months

Wipro BUY. Performance Highlights. CMP Target Price `539 `680. 4QFY2016 Result Update IT. 3-year price chart. Key financials (Consolidated, IFRS)

Amber Enterprises India Ltd

Tech Mahindra ACCUMULATE. Performance Highlights. CMP Target Price `659 `693. 3QFY2012 Result Update IT. Key financials (Consolidated, Indian GAAP)

Rallis India NEUTRAL. Performance Highlights CMP. `237 Target Price - 1QFY2018 Result Update Agrichemical. Investment Period - 3-year price chart

Tech Mahindra ACCUMULATE. Performance Highlights CMP. `955 Target Price `1,070. 2QFY2013 Result Update IT. Investment Period 12 months

ITC ACCUMULATE. Performance Highlights CMP. `257 Target Price `284. 3QFY2017 Result Update FMCG. Investment Period 12 Months

Parag Milk Foods BUY. Performance Update CMP. `256 Target Price `330. 2QFY2019 Result Update Dairy Products. Investment Period 12 Months

Rallis India NEUTRAL. Performance Highlights CMP. `215 Target Price - 3QFY2017 Result Update Agrichemical. Investment Period - 3-year price chart

Rallis India NEUTRAL. Performance Highlights CMP. `242 Target Price - 4QFY2017 Result Update Agrichemical. Investment Period - 3-year price chart

Mahindra & Mahindra Ltd.

TV Today Network BUY. Performance Update CMP. `323 Target Price `498. 3QFY2019 Result Update Media. Investment Period 12 Months

Inox Wind BUY. Performance Highlights. CMP Target Price `390 `505. 2QFY2016 Result Update Capital Goods. 3 year price chart

Mahindra & Mahindra Ltd.

Hindustan Media Ventures

GMM Pfaudler Limited BUY. Performance Update CMP. `945 Target Price ` QFY2019 Result Update Industrial Machinery. Investment Period 12 Months

Rallis India SELL. Performance Highlights. `231 Target Price 189 CMP. 2QFY2018 Result Update Agrichemical. Investment Period 12 months

KPIT Cummins ACCUMULATE. Performance Highlights CMP. `121 Target Price `132. 2QFY2013 Result Update IT. Investment Period 12 Months

Parag Milk Foods BUY. Performance Update CMP. `324 Target Price `410. 1QFY2019 Result Update Dairy Products. Investment Period 12 Months

Garware Wall Ropes ACCUMULATE. Performance Highlights CMP. `550 Target Price `618. 2QFY2017 Result Update Textile. Investment Period 12 months

Maruti Suzuki India BUY. Performance Update. CMP `9,315 Target Price `10,820. 1QFY2019 Result Update Automobile. Historical share price chart

Tata Steel NEUTRAL. Performance Highlights CMP. `226 Target Price - 2QFY2016 Result Update Steel. Investment Period - 3-year price chart

Coal India ACCUMULATE. Performance Highlights CMP. `338 Target Price `380. Outlook and valuation. 2QFY2016 Result Update Mining

Maruti Suzuki India BUY. Performance Update. CMP `6,705 Target Price `8,552. 2QFY2019 Result Update Automobile. Historical share price chart

Bata India BUY. Performance Update. CMP Target Price `842. 1QFY2019 Result Update Footwear. Historical share price chart.

Cadila Healthcare NEUTRAL. Performance Highlights CMP. `495 Target Price - 4QFY2017 Result Update Pharmaceutical.

Music Broadcast BUY. Performance Update. CMP Target Price `329 `475. 2QFY2019 Result Update Media. Historical share price chart.

Inox Wind BUY. Performance Highlights. CMP Target Price `242 `286. 4QFY2016 Result Update Capital Goods. 3 year price chart

Dr. Reddy s Laboratories

Music Broadcast BUY. Performance Update. CMP Target Price `293 `475. 3QFY2019 Result Update Media. Stock Info Sector Market Cap (Rs cr) Media

Blue Star Ltd BUY. Performance Update. CMP Target Price `703 `867. 1QFY2019 Result Update Cons. Durable. 3-year price chart.

TV Today Network BUY. Performance Update. CMP Target Price `315 `385. 2QFY2017 Result Update Media. Historical share price chart.

Bata India BUY. Performance Update. CMP `1,008 Target Price `1,243. 2QFY2019 Result Update Footwear. Historical share price chart.

Sanofi India NEUTRAL. Performance Highlights. CMP `4,007 Target Price - 2QCY2017 Result Update Pharmaceutical. 3-year price chart.

KPIT Cummins BUY. Performance Highlights CMP. `105 Target Price `135. 4QFY2013 Result Update IT. Investment Period 12 Months

Sanofi India NEUTRAL. Performance Highlights. CMP `4,007 Target Price - 3QCY2017 Result Update Pharmaceutical. Investment Period 12 months

Sanofi India NEUTRAL. Performance Highlights. CMP `4,301 Target Price - 4QCY2016 Result Update Pharmaceutical. Investment Period - 3-year price chart

Ambuja Cements ACCUMULATE. Performance Highlights. CMP Target Price `207 `233. 3QCY2015 Result Update Cement. Quarterly results (Standalone)

ACC BUY. Performance Highlights. CMP `1,397 Target Price `1,630. 3QCY2015 Result Update Cement

Reliance Communication

Asian Granito BUY. Performance Highlights CMP. `270 Target Price `351. Outlook and valuation. 3QFY2017 Result Update Ceramics

Procter & Gamble Hygiene & Health Care

Quick take. Ruchira Papers Ltd. BUY. Creating value through paper. Target Price. Investment Period 12 Months. 3 year daily price chart.

Amara Raja Batteries BUY. Performance Highlights. CMP `1,010 Target Price `1,167. 2QFY2017 Result Update Auto Ancillary. 3-year price chart

NIIT BUY. Performance Highlights CMP. `55 Target Price `68. 4QFY2011 Result Update Education. Investment Period 12 Months

Hero MotoCorp ACCUMULATE. Performance Highlights. CMP `3,226 Target Price `3,466. 3QFY2017 Result Update Automobile. 3-year price chart

Greenply Industries BUY. The plywood maker for growing India. Target Price. Initiating Coverage Plywood. 3-year price chart.

Goodyear India BUY. Company Update. CMP Target Price `515 `631. Company Update Tyres. 3-year Daily Price Chart. Key Financials

Sanofi India ACCUMULATE. Performance Highlights. CMP `4,410 Target Price `4,738. 1QCY2016 Result Update Pharmaceutical. 3-year price chart

Cadila Healthcare NEUTRAL. Performance Highlights CMP. `390 Target Price - 2QFY2017 Result Update Pharmaceutical. Investment Period -

Dr Reddy s Laboratories

Cadila Healthcare NEUTRAL. Performance Highlights CMP. `440 Target Price. 3QFY2017 Result Update Pharmaceutical. Investment Period -

Lupin BUY. Performance Highlights. CMP `1,493 Target Price `1,809. 2QFY2017 Result Update Pharmaceutical. 3-year price chart

ICICI Bank BUY. Performance Highlights. CMP Target Price `328 `416. 3QFY2018 Result Update Banking. 3-year price chart. Key financials (Standalone)

CCL Products BUY. Brewing Steadily. CMP Target Price `300 `360. Initiating Coverage Coffee. January 4, year price chart

Lupin 1QFY2018 Result Update

ICICI Bank BUY. Performance Highlights. CMP Target Price `343 `460. Q3FY2019 Result Update Banking. 3-year price chart. Exhibit 1: Key Financials

GAIL India NEUTRAL. Performance Highlights CMP. `363 Target Price - 2QFY2013 Result Update Oil & Gas. Investment Period -

Jindal Steel & Power BUY. CMP Target Price `200 `320. 1QFY2019 Result Update Steel & Power. Performance Update

Cipla REDUCE. Performance Highlights. CMP Target Price `564 `490. 2QFY2017 Result Update Pharmaceutical. Investment Period - 3-Year Daily Price Chart

LIC Housing Finance BUY. Performance Highlights. CMP Target Price `532 `630. 3QFY2017 Result Update HFC. 3-Year Daily Price Chart

Federal Bank BUY. Performance Highlights. Target Price. 1QFY2018 Result Update Banking. Stock Info Sector

Aurobindo Pharma ACCUMULATE. Performance Highlights. `780 Target Price CMP `855. 2QFY2019 Result Update Pharmaceutical. Investment Period 12 months

KEI Industries BUY. Performance Update. CMP Target Price `433 `508. 4QFY2018 Result Update Cable. Historical share price chart.

Axis Bank BUY. CMP Target Price `620 `750. Update Bank. Earnings to normalize with stabilizing credit costs. 3-year price chart.

Cadila Healthcare ACCUMULATE. Performance Highlights. CMP 860 Target Price QFY2013 Result Update Pharmaceutical. Key financials (Consolidated)

Graphite India BUY. Performance Highlights CMP. `93 Target Price `124. 4QFY2012 Result Update Capital Goods. Investment Period 12 Months

Quick take. VIP Industries BUY. Travelling smart on the luggage track. CMP Target Price `153 ` year daily price chart

Graphite India BUY. Performance Highlights. CMP Target Price `88 `109. 1QFY2012 Result Update Capital Goods

FY2017 FY2018E FY2019E

KEI Industries BUY. Performance Update. Target Price. 3QFY2018 Result Update Cable. Historical share price chart. Key Financials

LT Foods BUY. Performance Update. CMP Target Price `76 `128. 4QFY2018 Result Update Media

Future Supply Chain Solutions Ltd

Aurobindo Pharma BUY. Performance Highlights. `708 Target Price CMP `823. 2QFY2018 Result Update Pharmaceutical. Investment Period 12 months

Mahindra & Mahindra Ltd.

SpiceJet BUY. Performance Highlights CMP. `32 Target Price `43. 1QFY2013 Result Update Airlines. Investment Period 12 Months.

LT Foods BUY. Performance Update. CMP Target Price `92 `128. 3QFY2018 Result Update Media February 12, 2018

Aurobindo Pharma BUY. Performance Highlights CMP. `580 Target Price `823. 4QFY2017 Result Update Pharmaceutical. Investment Period 12 months

Sun Pharma BUY. Performance Highlights. `783 Target Price `944 CMP. 1QFY2017 Result Update Pharmaceutical. Investment Period 12 months

Goodyear India ACCUMULATE. Performance Highlights. CMP Target Price `326 `374. 1QCY2012 Result Update Tyres. Key financials

HDFC Bank BUY. Operating performance strong; improved NIM. CMP `2,268 Target Price `2,500. Q4FY2019 Result Update Banking. 3-year price chart

Hero MotoCorp ACCUMULATE. Performance Highlights. CMP `3,718 Target Price `4,130. 1QFY2018 Result Update Automobile. 3-year price chart

ICICI Bank BUY. Performance Highlights. CMP Target Price `307 `411. 1QFY2019 Result Update Banking. 3-year price chart. Key financials (Standalone)

HDFC Bank BUY. Performance Highlights. CMP `2,145 Target Price `2,500. Q3FY2019 Result Update Banking. 3-year price chart. Key financials (Standalone)

Sun Pharma BUY. Performance Highlights. `683 Target Price `847 CMP. 2QFY2017 Result Update Pharmaceutical. Investment Period 12 months

Transport Corporation of India

Dr. Reddy s Laboratories

HDFC Bank BUY. Performance Highlights. CMP `1,965 Target Price `2,350. Q2FY2019 Result Update Banking. 3-year price chart. Exhibit 1: Key Financials

Cairn India ACCUMULATE. Performance Highlights. CMP Target Price `338 `382. 2QFY2013 Result Update Oil & Gas. Quarterly highlights (Consolidated)

Sun Pharma BUY. Performance Highlights. `739 Target Price `944 CMP. 4QFY2016 Result Update Pharmaceutical. Investment Period 12 months

Matrimony.com Ltd BUY. A complete package from matchmaking to wedding. Target Price. Initiating Coverage Internet Software & Services

ACC NEUTRAL. Performance Highlights. CMP `1,261 Target Price - 4QCY2012 Result Update Cement. Quarterly results (Standalone) Investment Period -

MRF BUY. Performance Highlights. CMP `9,407 Target Price `11,343. Company Update Automobile. Key financials

TVS Motor Company BUY. Performance Highlights. CMP Target Price `39 `45. 2QFY2013 Result Update Automobile. Quarterly highlights (Standalone)

Sun Pharma NEUTRAL. Performance Highlights CMP. 1QFY2013 Result Update Pharmaceutical. `676 Target Price - Investment Period -

United Phosphorus ACCUMULATE. Performance Highlights `754. CMP Target Price. 2QFY2018 Result Update Agrichemical. 3-year price chart

Matrimony.com Ltd BUY. Performance Update. Target Price `1,016. 4QFY2018 Result Update Cable. Historical share price chart.

Transcription:

Oct-12 Jan-13 Apr-13 Jul-13 Oct-13 Jan-14 Apr-14 Jul-14 Oct-14 Jan-15 Apr-15 Jul-15 Oct-15 Jan-16 Apr-16 Jul-16 Oct-16 Jan-17 Apr-17 Jul-17 1QFY2018 Result Update IT July 18, 2017 Tata Consultancy Services (TCS) Performance highlights (` cr) 1QFY18 4QFY17 % chg (qoq) 1QFY17 % chg (yoy) Net revenue 29,584 29,642 (0.2) 29,305 1.0 Adj. EBITDA 7,065 8,147 (13.3) 7,971 (11.4) Adj. EBITDA margin (%) 25.1 27.5 (243.1) 27.2 (168.9) Adj. PAT 5,945 6,608 (10.0) 6,317 (5.9) For 1QFY2018, TCS posted below expectation results on the EBIT and net profit fronts. The company posted 3.1% sequential growth in USD revenues to US$4,591mn v/s. US$4,585mn expected, mostly volume lead (3.5% qoq growth). On Constant Currency terms, the company posted a 2.0% qoq growth. On profitability, the EBIT margins came in at 23.4% v/s. 24.2% expected, posting a qoq dip of 236bps. Impact of wage hikes and visa expenses, apart from rupee appreciation were the major drags on profitability. Consequently, PAT came in at `5,945cr v/s. `6,275cr expected, de-growth of 10.0% qoq. We maintain our Accumulate rating with a target price of `2,651. Quarterly highlights: Company posted 3.1% sequential growth in USD revenues to US$4,591mn v/s. US$4,585mn expected, mostly volume lead (3.5% qoq growth). On Constant Currency terms, the company posted a 2.0% qoq growth. In terms of geography, Latin America and Continental Europe posted a qoq growth of 2.8% and 5.9% respectively. Its key market USA posted a qoq growth of 1.7%. India and Asia Pacific posted a qoq growth of 1.5% and 1.2% respectively. On profitability, the EBIT margins came in at 23.4% v/s. 24.2% expected, posting a qoq dip of 236bps. Impact of wage hikes and visa expenses, apart from rupee appreciation were the major drags on profitability. Consequently, PAT came in at `5,945 v/s. `6,275cr expected, de-growth of 10.0% qoq. On operational front, the LTM attrition was at 11.6% in IT Services. Outlook and valuation: The Company has been cautiously optimistic regarding its outlook for FY2018, with key verticals like BFSI and Hi-Tech expected to post a recovery. Also, on the EBIT front the company is confident of managing the EBIT margins in the range of 26-28%. We expect TCS to post revenue CAGR of 8.5% in USD as well as INR terms over FY2017-19E. Hence, maintain our Accumulate recommendation. Key financials (Consolidated, IFRS) Y/E March (` cr) FY2016 FY2017 FY2018E FY2019E Net sales 1,08,646 1,17,966 1,27,403 1,38,870 % chg 14.8 8.6 8.0 9.0 Net profit 24,215 26,289 28,272 30,524 % chg 11.6 8.6 7.5 8.0 EBITDA margin (%) 28.3 27.5 27.6 27.6 EPS (`) 123.7 134.3 144.5 156.0 P/E (x) 19.4 17.9 16.6 15.4 P/BV (x) 6.4 5.3 4.9 4.6 RoE (%) 33.1 29.8 29.7 29.8 RoCE (%) 31.6 28.8 28.9 29.2 EV/Sales (x) 4.0 3.6 3.3 3.0 EV/EBITDA (x) 14.3 13.0 12.1 10.9 ; Note: CMP as of July 14, 2017 ACCUMULATE CMP `2,399 Target Price `2,651 Investment Period Stock Info Sector Bloomberg Code Shareholding Pattern (%) 12 Months Market Cap (` cr) 4,58,606 Net Debt (` cr) -45,288 Beta 0.6 52 Week High / Low 2,834/2,055 Avg. Daily Volume 1,10,516 Face Value (`) 1 BSE Sensex 32,021 Nifty 9,886 Reuters Code Promoters 73.6 MF / Banks / Indian Fls 5.5 FII / NRIs / OCBs 17.0 Indian Public / Others 4.0 Abs.(%) 3m 1yr 3yr Sensex 28.0 14.6 29.0 TCS (1.1) (4.8) 4.1 3-Year Daily Price Chart 3,000 2,500 2,000 1,500 1,000 500 0 Sarabjit kour Nangra +91 22 3935 7800 Ext: 6806 sarabjit @angelbroking.com IT TCS.BO TCS@IN Please refer to important disclosures at the end of this report 1

Exhibit 1: 1QFY2018 performance (Consolidated, IFRS) (` cr) 1QFY2018 4QFY2017 % chg (qoq) 1QFY2017 % chg (yoy) FY2017 FY2016 % chg(yoy) Net revenue 29,584 29,642 (0.2) 29,305 1.0 1,17,966 1,08,646 8.6 Cost of revenue 16,792 16,153 4.0 16,312 2.9 65,402 59,459 10.0 Gross profit 12,792 13,489 (5.2) 12,993 (1.5) 52,564 49,187 6.9 SG&A expense 5,379 5,342 0.7 5,156 4.3 20,755 18,956 9.5 EBITDA 7,413 8,147 (9.0) 7,837 (5.4) 31,809 30,231 5.2 Dep. and amortisation 499 520 (4.0) 490 1.8 1,485 1,441 3.1 EBIT 6,914 7,627 (9.3) 7,347 (5.9) 30,324 28,790 5.3 Other income 932 989 (5.8) 963 (3.2) 4,189 3,050 37.3 PBT 7,846 8,616 (8.9) 8,310 (5.6) 34,513 31,840 8.4 Income tax 1,896 1,994 (4.9) 1,992 (4.8) 8,156 7,503 8.7 PAT 5,950 6,622 (10.1) 6,318 (5.8) 26,357 24,337 8.3 Earnings in affiliates - - - - - - - Minority interest 5 14 1-68 123 Reported PAT 5,945 6,608 (10.0) 6,317 (5.9) 26,289 24,215 8.6 Adj. PAT 5,945 6,608 (10.0) 6,317 (5.9) 26,289 24,215 8.6 EPS 30.4 33.7 (10.0) 32.3 (5.9) 133.4 123.2 8.3 Gross margin (%) 43.2 45.5 (227)bp 44.3 (110)bp 44.6 45.3 (71)bp EBITDA margin (%) 25.1 27.5 (243)bp 26.7 (169)bp 27.0 27.8 (86)bp EBIT margin (%) 23.4 25.7 (236)bp 25.1 (170)bp 25.7 26.5 (79)bp Exhibit 2: Actual v/s Angel estimates (` cr) Actual Estimate Var. (%) Net revenue 29,584 29,600 (0.1) EBIT margin (%) 23.4 24.2 (88)bps Adj. PAT 5,945 6,275 (5.3) Numbers just in-line with expectations TCS results were below expectations on the EBIT and net profit fronts. The company posted 3.1% sequential growth in USD revenues to US$4,591mn v/s. US$4,585mn expected, mostly volume lead (3.5% qoq growth). On Constant Currency terms, the company posted a 2.0% qoq growth. In Rupee terms, revenues are expected to come in at `29,548cr v/s. `29,600cr expected, down 0.2% qoq. In terms of verticals, on CC basis, the growth registered by the company in respective segments was, BFSI (2.3% qoq), Retail & CPG (2.0% qoq), Communication & Media (3.9% qoq), Manufacturing (3.8% qoq), Life Sciences & Healthcare (4.7% qoq), Hi-Tech (3.7% qoq), Energy Utilities (7.6% qoq), Travel & Hospitality (7.0% qoq). In terms of geography, on CC basis, qoq growth was North America (1.7% qoq), Latin America (2.8% qoq), UK (0.7% qoq), Continental Europe (5.9% qoq), India (1.5% qoq), Asia Pacific (1.2% qoq), MEA (0.7% qoq). July 18, 2017 2

(%) (%) TCS 1QFY2018 Result Update Exhibit 3: Trend in volume and revenue growth (qoq) 8 7 6 5 3.7 3.5 4 3 3.1 3.4 1.7 2 1.0 1 1.3 1.5 0 0.3-1 1QFY17 2QFY17 0.3 3QFY17 4QFY17 1QFY18 Volume growth Revenue growth (USD terms) Exhibit 4: Revenue drivers for 1QFY2018 4 3.5 3 3.1 2 1 1.5 0-1 -2-3 (1.9) Volume Currency impact CC realization Total revenue growth In Communication, weakness was seen in UK, Europe and Asia Pacific, while in Healthcare, US slowed down. However, both these factors are one-offs. Revenue from Digital grew by 7.6% qoq, and it now constitutes to 17.9% of total revenue. Exhibit 5: Revenue growth (Industry wise on CC basis) % to revenue % chg (CC qoq) % chg (yoy) BFSI 32.9 2.3 5.1 Manufacturing 7.5 3.8 10.2 Communication & Media 7.3 3.9 11.6 Life sciences and healthcare 7.1 4.7 10.7 Retail and CPG 12.2 2.0 (3.4) Transportation & Hospitality 3.5 3.7 16.5 Energy and utilities 4.0 4.0 20.3 Technology & Services 7.9 3.7 8.2 Regional Markets & Others 17.6 (3.6) 5.5 July 18, 2017 3

Geography wise growth in INR sales in key geographies was as follows: USA (1.7% qoq on CC basis), Latin America (2.8% qoq on CC basis), UK (0.7% qoq on CC basis), India (1.5% qoq on CC basis), and MEA (0.7% qoq on CC basis). However, Continental Europe and Asia Pacific posted growth of 5.9% qoq and 1.2% qoq on CC basis respectively. Exhibit 6: Revenue growth (Geography wise in INR terms) % of revenue % chg (CC qoq) % chg (yoy) U.S. 52.5 1.7 3.5 Latin America 2.1 2.8 8.0 U.K. 13.9 0.7 6.3 Continental Europe 12.5 5.9 16.5 India 7.0 1.5 13.3 Asia Pacific 9.5 1.2 4.7 MEA 2.5 0.7 8.9 Attrition rate appreciates In 1QFY2018, TCS witnessed a gross addition of 11,202 employees and net addition of (1,414) employees, taking its total employee base to 3,85,809. During the quarter, the attrition rate (last twelve month [LTM] basis) for the company increased to 12.5% from 11.5% in 4QFY2017. Exhibit 7: Hiring and attrition trend Particulars 1QFY17 2QFY17 3QFY17 4QFY17 1QFY18 Gross addition 17,792 22,665 18,362 20,093 11,202 Net addition 8,236 9,440 6,978 8,726 (1,414) Total employee base 3,62,079 3,71,519 3,78,497 3,87,223 3,85,809 Attrition (%) - LTM basis 13.6 12.9 12.2 11.5 12.4 Margin dips On the operating front, the company reported EBITDA and EBIT margins at 25.1% and 23.4%, i.e. a contraction of 243bps and 236bps qoq respectively. The break up across cost items is Employee costs (200bps), Rent expenses (30bps) and Visas and consultants (30bps). However, for FY2018, the company has guided the EBIT margins to be in the range of 26-28%. July 18, 2017 4

(%) TCS 1QFY2018 Result Update Exhibit 8: Adj. Margin profile 30 26.7 27.2 27.7 27.5 25.1 25 20 25.1 26.0 26.0 25.7 23.4 15 1QFY17 2QFY17 3QFY17 4QFY17 1QFY18 EBITDA margin EBIT margin Client metrics The client pyramid during the quarter witnessed a qualitative improvement with client additions seen in the higher revenue brackets. The clients in US$100mn+ revenue band increased by 1 and in US$10mn+ revenue band increased by 12. TCS won four large deals in BFSI in 1QFY2018, but cited that the pipeline remains short. The pipeline for Insurance is strong, which can result in a stronger 2HFY2018. Exhibit 9: Client pyramid 1QFY17 2QFY17 3QFY17 4QFY17 1QFY18 US$1mn 5mn 408 410 426 438 441 US$5mn 10mn 141 154 154 149 142 US$10mn 20mn 119 110 114 120 132 US$20mn 50mn 102 107 106 106 105 US$50mn 100mn 40 42 46 49 49 US$100mn plus 37 36 34 35 36 July 18, 2017 5

Investment Argument Guidance Cautious optimism: The management refrained from giving any guidance for FY2018, however it expects a bounce back of the key verticals like BFSI, Communications and Hi-Tech. Digital also continues to see a good traction. On EBIT front, the company expects to manage its margins in 26-28% range. We expect the company to post a US$ revenue CAGR of 8.5% over FY2017-19E. Management Reggie: With Mr. Natarajan Chandrasekaran being the Chairman of Tata Sons since February 21, 2017, CFO Mr. Rajesh Gopinathan has taken charge as the CEO of the company. He started his professional career with TCS in 2001 and was appointed as the CFO in February 2013. TCS also announced N G Subramanian as the COO of the company. Thus, the new targets under the new CEO will have a bearing on the performance of the company. Growth fundamentals intact: Despite the near term uncertainty arising out of Brexit and new macro dynamics in US, TCS remains optimistic to make a comeback after current cyclical headwinds are behind. Long term drivers of tech spending will remain intact and new growth areas are emerging. Strength in Digital bounced back after seeing some weakness in 2QFY2017. Revenue from Digital grew by 7.6% qoq and it now constitutes to 17.9% of total revenue. Thus, the company has invested well to reap the benefits over long term. Outlook and valuation Over FY2017-19E, we expect TCS to post revenue CAGR of 8.5% in USD and INR terms. The company highlighted that it stands comfortable of sustaining the EBIT margin in the range of 26-28%. On the EBIT and PAT fronts, we expect the company to post 8.7% and 7.8% CAGR over FY2017-19E respectively. The stock is trading at 15.4x FY2019E EPS of `156. We maintain our Accumulate recommendation. Exhibit 10: Key assumptions FY2018E FY2019E Revenue growth (USD) 8.0 9.0 USD-INR rate (realized) 67.1 67.1 Revenue growth (`) 8.0 9.0 EBITDA margin (%) 27.6 27.6 Tax rate (%) 23.5 23.5 EPS growth (%) 7.5 8.0 July 18, 2017 6

Jan-09 May-09 Sep-09 Jan-10 May-10 Sep-10 Jan-11 May-11 Sep-11 Jan-12 May-12 Sep-12 Jan-13 May-13 Sep-13 Jan-14 May-14 Sep-14 Jan-15 May-15 Sep-15 Jan-16 May-16 Sep-16 Jan-17 May-17 (`) TCS 1QFY2018 Result Update Exhibit 11: One-year forward PE chart 4,000 3,500 3,000 2,500 2,000 1,500 1,000 500 0 Price 25x 21x 16x 11x 6x Exhibit 12: Recommendation summary Company Reco CMP Tgt. price Upside FY2019E FY2019E FY2017-19E FY2019E FY2019E (`) (`) (%) EBITDA (%) P/E (x) EPS CAGR (%) EV/Sales (x) RoE (%) HCL Tech Buy 851 1,014 19.1 20.9 12.6 6.2 1.8 20.6 Infosys Buy 972 1,179 21.3 26.0 14.0 5.3 2.2 19.6 TCS Accumulate 2,399 2,651 10.5 27.6 15.4 7.8 3.0 29.8 Tech Mahindra Buy 388 533 37.5 15.0 10.2 8.6 1.0 16.3 Wipro Accumulate 260 280 7.9 20.3 13.6 4.4 1.2 13.4 July 18, 2017 7

Company background TCS is Asia's largest IT services provider and is amongst the top 10 technology firms in the world. The company has a global footprint with an employee base of over 3lakh professionals, offering services to more than 1,000 clients across various industry segments. The company has one of the widest portfolios of service offerings, spanning across the entire IT service value chain from traditional application development and maintenance to consulting and package implementation to products and platforms. July 18, 2017 8

Profit & Loss statement (Consolidated, IFRS) Y/E March (` cr) FY2015 FY2016 FY2017 FY2018E FY2019E Net sales 94,648 1,08,646 1,17,966 1,27,403 1,38,870 Cost of revenue 50,599 58,952 64,764 68,798 74,990 Gross profit 44,049 49,695 53,202 58,606 63,880 % of net sales 46.5 45.7 45.1 46.0 46.0 SGA expenses 17,353 18,956 20,755 23,442 25,552 % of net sales 18.3 17.4 17.6 18.4 18.4 EBITDA 26,696 30,738 32,447 35,163 38,328 % of net sales 28.2 28.3 27.5 27.6 27.6 Dep. and amortization 1272 1948 2123 2293 2500 % of net sales 1.3 1.8 1.8 1.8 1.8 EBIT 25,424 28,790 30,324 32,870 35,828 % of net sales 26.9 26.5 25.7 25.8 25.8 Other income, net 3140 3050 4189 4189 4189 Profit before tax 28,564 31,840 34,513 37,059 40,017 Provision for tax 6,083 7,503 8,156 8,709 9,404 % of PBT 21.3 23.6 23.6 23.5 23.5 PAT 22,481 24,338 26,357 28,350 30,613 Minority interest 205 123 68 78 89 Extra-ordinary (Exp.)/ Inc. -2627.9 Reported PAT 19,648 24,215 26,289 28,272 30,524 Adj. PAT 21,696 24,215 26,289 28,272 30,524 Diluted EPS (`) 110.9 123.7 134.3 144.5 156.0 July 18, 2017 9

Balance sheet (Consolidated, IFRS) Y/E March (` cr) FY2015 FY2016 FY2017 FY2018E FY2019E Assets Cash and cash equivalents 1,862 1,862 3,597.0 4,500.0 5,000.0 Other current financial assets 16,383 4,833 - - - Accounts receivable 20,440 24,073 22,684 31,694 31,695 Unbilled revenues 3,827 3,992 5,351 5,348 5,349 Other current assets 6,414 5,975 7,258 7,258 7,258 Property and equipment 11,572 11,790 11,741 12,741 13,741 Intangible assets and goodwill 3,931 3,946 3,768 3,768 3,768 Investments 9,619 22,822 41,980 39,267 46,761 Other non current assets 906 11,919 8,974 8,974 8,974 Total assets 74,954 91,212 1,05,353 1,13,550 1,22,545 Liabilities Current liabilities 14,428 15,407 14,294 15,288 16,664 Short term borrowings 243 162 218 218 218 Redeemable preference shares - (0) - 1 2 Long term debt 114 83 71 71 71 Other non current liabilities 1,778 2,017 2,089 2,442 2,662 Minority interest 914 354 366 444 533 Shareholders funds 57,477 73,190 88,315 95,086 1,02,397 Total liabilities 74,954 91,212 1,05,353 1,13,550 1,22,545 July 18, 2017 10

Cash flow statement (Consolidated, IFRS) Y/E March (` cr) FY2015 FY2016 FY2017 FY2018E FY2019E Pre-tax profit from oper. 22,481 24,338 26,357 28,350 30,613 Depreciation 1,272 1,948 2,123 2,293 2,500 Exp. (deferred)/written off 160 174 - - - Pre tax cash from oper 23,913 26,460 28,480 30,643 33,113 Other inc./prior period ad 1,272 1,948 2,123 2,293 2,500 Net cash from operations 25,185 28,408 30,604 32,937 35,613 Tax 6,083 7,503 8,156 8,709 9,404 Cash profits 19,102 20,905 22,448 24,228 26,209 (Inc)/dec in acc. recv. (2,210) (3,633) 1,389 (9,010) (1) (Inc)/dec in unbilled rev. 179 (165) (1,359) 3 (1) (Inc)/dec in oth. current asst. (6,414) 439 (1,283) - - Inc/(dec) in current liab. (1,207) (218) 49 (1,000) (1,000) Net trade working capital (9,652) (3,577) (1,204) (10,007) (1,002) Cash flow from opert. actv. 9,450 17,328 21,243 14,221 25,207 (Inc)/dec in fixed assets (1,207) (218) 49 (1,000) (1,000) (Inc)/dec in investments (4,446) (1,653) (14,325) 2,713 (7,494) (Inc)/dec in intangible asst. (226) 16 (178) - - (Inc)/dec in non-cur.asst. (906) (11,013) 2,945 - - Cash flow from invt. actv. (6,786) (12,869) (11,509) 1,713 (8,494) Inc/(dec) in debt 61 (113) 44 - - Inc/(dec) in equity 223 (559) 12 78 89 Inc/(dec) in minority int. (19,923) (18,415) (19,993) (21,501) (23,213) Dividends 16,976 14,629 10,202 5,489 6,411 Cash flow from finan. actv. (2,664) (4,459) (9,735) (15,934) (16,713) Cash generated/(utilized) 393-1,735 903 500 Cash at start of the year 1,469 1,862 1,862 3,597 4,500 Cash at end of the year 1,862 1,862 3,597 4,500 5,000 July 18, 2017 11

Key ratios Y/E March FY2015 FY2016 FY2017 FY2018E FY2019E Valuation ratio(x) P/E (on FDEPS) 21.6 19.4 17.9 16.6 15.4 P/CEPS 22.5 18.0 16.5 15.4 14.2 P/BVPS 8.2 6.4 5.3 4.9 4.6 Dividend yield (%) 1.8 1.7 1.8 2.0 2.1 EV/Sales 4.6 4.0 3.6 3.3 3.0 EV/EBITDA 16.5 14.3 13.0 12.1 10.9 EV/Total assets 5.9 4.8 4.0 3.7 3.4 Per share data (`) EPS 110.9 123.7 134.3 144.5 156.0 Cash EPS 106.8 133.6 145.1 156.0 168.6 Dividend 43.5 40.2 43.6 46.9 50.6 Book value 294 374 451 486 523 Dupont analysis Tax retention ratio (PAT/PBT) 0.8 0.8 0.8 0.8 0.8 Cost of debt (PBT/EBIT) 1.1 1.1 1.1 1.1 1.1 EBIT margin (EBIT/Sales) 0.3 0.3 0.3 0.3 0.3 Asset turnover ratio (Sales/Assets) 1.3 1.2 1.1 1.1 1.1 Leverage ratio (Assets/Equity) 1.3 1.2 1.2 1.2 1.2 Operating ROE 39.1 33.3 29.8 29.8 29.9 Return ratios (%) RoCE (pre-tax) 33.9 31.6 28.8 28.9 29.2 Angel RoIC 54.0 46.7 50.7 47.1 50.6 RoE 34.2 33.1 29.8 29.7 29.8 Turnover ratios(x) Asset turnover (fixed assets) 8.2 9.2 10.0 10.0 10.1 Receivables days 79 81 70 91 83 July 18, 2017 12

Research Team Tel: 022-39357800 E-mail: research@angelbroking.com Website: www.angelbroking.com DISCLAIMER Angel Broking Private Limited (hereinafter referred to as Angel ) is a registered Member of National Stock Exchange of India Limited, Bombay Stock Exchange Limited and Metropolitan Stock Exchange Limited. It is also registered as a Depository Participant with CDSL and Portfolio Manager with SEBI. It also has registration with AMFI as a Mutual Fund Distributor. Angel Broking Private Limited is a registered entity with SEBI for Research Analyst in terms of SEBI (Research Analyst) Regulations, 2014 vide registration number INH000000164. Angel or its associates has not been debarred/ suspended by SEBI or any other regulatory authority for accessing /dealing in securities Market. Angel or its associates/analyst has not received any compensation / managed or co-managed public offering of securities of the company covered by Analyst during the past twelve months. This document is solely for the personal information of the recipient, and must not be singularly used as the basis of any investment decision. Nothing in this document should be construed as investment or financial advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in the securities of the companies referred to in this document (including the merits and risks involved), and should consult their own advisors to determine the merits and risks of such an investment. Reports based on technical and derivative analysis center on studying charts of a stock's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's fundamentals. Investors are advised to refer the Fundamental and Technical Research Reports available on our website to evaluate the contrary view, if any. The information in this document has been printed on the basis of publicly available information, internal data and other reliable sources believed to be true, but we do not represent that it is accurate or complete and it should not be relied on as such, as this document is for general guidance only. Angel Broking Pvt. Limited or any of its affiliates/ group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Angel Broking Pvt. Limited has not independently verified all the information contained within this document. Accordingly, we cannot testify, nor make any representation or warranty, express or implied, to the accuracy, contents or data contained within this document. While Angel Broking Pvt. Limited endeavors to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. This document is being supplied to you solely for your information, and its contents, information or data may not be reproduced, redistributed or passed on, directly or indirectly. Neither Angel Broking Pvt. Limited, nor its directors, employees or affiliates shall be liable for any loss or damage that may arise from or in connection with the use of this information. Disclosure of Interest Statement TCS 1. Financial interest of research analyst or Angel or his Associate or his relative No 2. Ownership of 1% or more of the stock by research analyst or Angel or associates or relatives No 3. Served as an officer, director or employee of the company covered under Research No 4. Broking relationship with company covered under Research No Ratings (Based on expected returns Buy (> 15%) Accumulate (5% to 15%) Neutral (-5 to 5%) over 12 months investment period): Reduce (-5% to -15%) Sell (< -15) July 18, 2017 13